- Home
- FDS vs RPRX Comparison
FDS vs RPRX Comparison
Compare FDS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDS
- RPRX
- Stock Information
- Founded
- FDS 1978
- RPRX 1996
- Country
- FDS United States
- RPRX United States
- Employees
- FDS N/A
- RPRX N/A
- Industry
- FDS Computer Software: Programming Data Processing
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- FDS Technology
- RPRX Health Care
- Exchange
- FDS Nasdaq
- RPRX Nasdaq
- Market Cap
- FDS 17.6B
- RPRX 16.0B
- IPO Year
- FDS 1996
- RPRX 2020
- Fundamental
- Price
- FDS $285.08
- RPRX $37.31
- Analyst Decision
- FDS Hold
- RPRX Strong Buy
- Analyst Count
- FDS 10
- RPRX 4
- Target Price
- FDS $356.78
- RPRX $44.50
- AVG Volume (30 Days)
- FDS 767.2K
- RPRX 2.4M
- Earning Date
- FDS 09-18-2025
- RPRX 11-05-2025
- Dividend Yield
- FDS 1.54%
- RPRX 2.36%
- EPS Growth
- FDS 11.79
- RPRX 54.86
- EPS
- FDS 15.55
- RPRX 2.32
- Revenue
- FDS $2,321,748,000.00
- RPRX $2,305,243,000.00
- Revenue This Year
- FDS $6.17
- RPRX $35.14
- Revenue Next Year
- FDS $5.44
- RPRX $1.24
- P/E Ratio
- FDS $18.35
- RPRX $16.03
- Revenue Growth
- FDS 5.39
- RPRX 3.02
- 52 Week Low
- FDS $272.50
- RPRX $24.05
- 52 Week High
- FDS $499.87
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- FDS 38.48
- RPRX 59.95
- Support Level
- FDS $285.50
- RPRX $36.69
- Resistance Level
- FDS $296.80
- RPRX $37.69
- Average True Range (ATR)
- FDS 7.61
- RPRX 0.63
- MACD
- FDS 3.89
- RPRX 0.13
- Stochastic Oscillator
- FDS 48.91
- RPRX 84.55
About FDS FactSet Research Systems Inc.
FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for roughly 82% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.